slotkoers
Andere beurzen
|
||
- CAD | - |
|
20/06 | MediPharm Labs verwerft rechten voor geavanceerde medische cannabisproducten van Remidose Aerosols | MT |
15/05 | Transcript : MediPharm Labs Corp., Q1 2024 Earnings Call, May 15, 2024 |
Omzet 2024 * | 43,84 mln. 32,1 mln. 29,97 mln. | Omzet 2025 * | 54,94 mln. 40,23 mln. 37,56 mln. | Marktkapitalisatie | 32,4 mln. 23,72 mln. 22,15 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -8 mln. -5,86 mln. -5,47 mln. | Nettowinst (verlies) 2025 * | -3 mln. -2,2 mln. -2,05 mln. | EV/omzet 2024 * | 0,74 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 0,59 x |
K/w-verhouding 2024 * |
-4
x | K/w-verhouding 2025 * |
-8
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 95,47% |
Recentste transcriptie over Medipharm Labs Corp
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Pidduck
CEO | Chief Executive Officer | - | 20-04-22 |
Greg Hunter
DFI | Director of Finance/CFO | - | 08-02-21 |
Keith Strachan
PSD | President | - | 01-10-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Michael Bumby
BRD | Director/Board Member | 60 | 01-04-23 |
David Pidduck
CEO | Chief Executive Officer | - | 20-04-22 |
Shelley Martin
BRD | Director/Board Member | - | 22-06-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+29,76% | 5,68 mld. | |
-32,34% | 3,59 mld. | |
-2,23% | 3,12 mld. | |
-25,26% | 2,62 mld. | |
-10,88% | 2,3 mld. | |
+40,09% | 1,88 mld. | |
+40,90% | 1,45 mld. | |
-15,16% | 1,39 mld. | |
+42,86% | 1,37 mld. |
- Beurs
- Aandelen
- Koers LABS
- Koers